Skip to main content


Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Figure 1 | Journal of Translational Medicine

Figure 1

From: First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity

Figure 1

First-line chemo-immunotherapy: drug administration schedule. The repeated single doses of IMP321 (0.25, 1.25 and 6.25 mg s.c. 12 × q14) were administered on D2 and D16 of the 28-day paclitaxel cycle, i.e. on the day after chemotherapy. A fixed dose of paclitaxel (80 mg/m2) was given as a weekly, 3 weeks out of 4, chemotherapy regimen for 6 cycles.

Back to article page